|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 132.88 USD | -1.07% |
|
+2.54% | +8.89% |
| 28/07 | Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial | MT |
| 28/07 | Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating | MT |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 166,768 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 9.51% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 176,365 | 166,768 | 156,812 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 4% | -5.44% | -5.97% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -48.4x | 17x | 15.6x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 8.49x | 6.63x | 5.35x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 1.71x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 5.48x | 5.16x | 4.89x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 5.8x | 5.16x | 4.6x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 32x | 9.29x | 8.73x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 63.7x | 10.7x | 9.37x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | 218x | 12.6x | 11.1x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | 0.46% | 7.95% | 8.97% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.296 | 3.409 | 3.102 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.45% | 2.54% | 2.31% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -2.775 | 7.887 | 8.608 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -119% | 43.2% | 36% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,425 | 32,297 | 34,107 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 5,510 | 17,953 | 17,972 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 2,771 | 15,584 | 16,737 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -3,391 | 9,779 | 10,495 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 9,597 | - | -9,955 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 134.32 | 134.32 | 134.32 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,241,570 | - | - |
| Announcement Date | 1/2/22 | 2/2/23 | 6/2/24 | 11/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -48.4x | 5.8x | 32.01x | 2.45% | 167B | |
| 36.25x | 12.94x | 27.18x | 0.55% | 1,089B | |
| 28.59x | 6.53x | 18.09x | 2.01% | 643B | |
| 33.13x | 7.75x | 15.94x | 2.61% | 465B | |
| 20.2x | 4.86x | 12.04x | 2.72% | 359B | |
| 22.65x | 5.84x | 14.57x | 2.74% | 303B | |
| 22.03x | 4.53x | 12.8x | 1.93% | 267B | |
| 14.79x | 5.48x | 11.3x | 3.38% | 226B | |
| 25.81x | 6.73x | 11.86x | 2.57% | 212B | |
| 12.82x | 3.13x | 7.91x | 6.82% | 144B | |
| Average | 16.79x | 6.36x | 16.37x | 2.78% | 387.5B | |
| Weighted average by Cap. | 24.74x | 7.92x | 18.67x | 2.1% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
